Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
INDIANAPOLIS, May 16, 2011 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. PARAMOUNT data will be included in the ASCO-sponsored press briefing the morning of June 5 followed by a presentation during the Lung Cancer Oral Abstract Session at ASCO later the same day.
At ASCO, Lilly will present the latest research results on ALIMTAÃ‚® (pemetrexed for injection) and GEMZARÃ‚® (gemcitabine for injection), as well as ERBITUXÃ‚® (cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.
“Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer,” said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. “We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly’s focus on tailored therapies, and commitment to addressing unmet needs in cancer care.”
ALIMTA Oral Abstract Session:
- Abstract # CRA7510: Sunday, June 5, 2011, 11:30 – 11:45 AM
- PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
- Author/Speaker: L. G. Paz-Ares, F. de Marinis, M. Dedui, M. Thomas, J.P. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli
- Location: Hall D1
This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly’s current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
SOURCE Eli Lilly and Company